A population-based cohort study emulating a target trial estimated the effect of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) compared with sodium-glucose cotransporter-2 (SGLT-2) inhibitors on the risk for gastroesophageal reflux…
Researchers have found in a new cohort study that higher exposure to anticholinergic medications was associated with an accelerated decline in physical performance. This decline was clinically meaningful, highlighting the…
Taiwan: A large-scale cohort study published in JAMA Network Open suggests that the use of GLP-1 receptor agonists, specifically semaglutide and tirzepatide, may offer protective benefits beyond blood sugar control…
USA: A recent analysis from the AZALEA-TIMI 71 trial, published in the Journal of the American College of Cardiology (JACC), highlights that the novel long-acting factor XI inhibitor abelacimab may…
A new study published in the journal of BMC Cardiovascular Diabetology revealed that an elevated stress hyperglycemia ratio (SHR) is linked to increased early mortality in cardiovascular disease patients, even…
A new study published in the journal of Diabetes Research and Clinical Practice showed that higher stroke risk is associated with greater body roundness index (BRI), particularly in people with…
Researchers have found in a 3-year phase 3 trial that palopegteriparatide (TransCon PTH) showed sustained improvements in biochemical markers, kidney function, and quality of life in adults with hypoparathyroidism. Already…
A randomized controlled trial (RCT) evaluated whether vaporized nicotine products (VNPs) are more effective than nicotine replacement therapies (NRT) for smoking cessation among people experiencing social disadvantage. The researchers found…
Gorakhpur: The Uttar Pradesh government has suspended Gorakhpur's drug inspector Rahul Kumar with immediate effect, after the Food Safety & Drug Administration (FSDA) unveiled serious lapses within his department. Official…
AstraZeneca announced that baxdrostat, a selective aldosterone synthase inhibitor, met its primary and all secondary endpoints in the BaxHTN Phase III trial, effectively lowering blood pressure in patients with uncontrolled…